drugset
drugset / Trial / NCT04558216

Evaluation of Effect of Rifampin on the Pharmacokinetics of Vonoprazan in Healthy Participants

NCT04558216 ↗

Phase 1 Withdrawn Phathom Pharmaceuticals, Inc.
NaSingle-groupOpen-labelBasic science

Summary

The primary objective of this study is to assess the effect of multiple doses of rifampin on the pharmacokinetics of vonoprazan in healthy participants.

Timeline

Start
2020-09-30
Primary completion
2021-02-07
Completion
2021-02-19

Outcome

Outcome not reported

Stopped: “Withdrawn due to unavailability of rifampin for clinical trial use”

Drugs

EvaluationDrugModalityDoseRoute
Subject Rifampicin Small molecule 600 mg Oral
Subject Vonoprazan Other / unclassified 20 mg Oral

Indications

No indication recorded.